ALMR · Alamar Biosciences, Inc.

Alamar Biosciences, Inc. is pursuing an expansion of its initial public offering through this S-1MEF filing under Rule 462(b), registering an additional 2,156,250 shares of common stock at a proposed maximum offering price of $17.00 per share, representing $36,656,250 in aggregate value. This supplements the earlier effective Registration Statement (File No. 333-294697), which covered $183,281,250, bringing the total registered offering closer to $220 million while staying within the 20% increase limit allowed by Rule 462(b). The inclusion of 281,250 shares for the underwriters' overallotment option provides flexibility for stabilizing post-IPO trading. The filing confirms the company's status as an emerging growth company, non-accelerated filer, and smaller reporting company, which affords reduced disclosure and compliance burdens under the JOBS Act. Headquartered at 47071 Bayside Parkway in Fremont, California, Alamar operates in SIC code 3826, indicative of laboratory analytical instruments in the life sciences sector. Leadership is anchored by founder Yuling Luo, Ph.D., who serves as Chairman and CEO, alongside CFO Justin McAnear and President Timothy 'Tod' White, with a board including directors like Rebecca Chambers, Shiping Chen, Ph.D., and others. Cooley LLP provides a clean legal opinion that the shares, upon issuance against payment as described, will be validly issued, fully paid, and nonassessable under Delaware General Corporation Law. Ernst & Young LLP consents to the use of their audit report on the company's consolidated financial statements, dated March 12, 2026 (updated for a reverse stock split noted April 13, 2026), incorporated from the prior filing. This Rule 462(b) filing underscores the IPO's momentum, enabling as-soon-as-practicable commencement of sales post-effectiveness, with no delayed or continuous offering indicated. For investors, the move signals strong underwriter confidence in demand, as additional shares are registered without needing a full prospectus amendment, minimizing delays. The Fremont base positions the company in a key biotech hub, though specific business details, financial metrics, use of proceeds, and risks remain in the incorporated earlier prospectus. Governance appears standard with power of attorney executed by the CEO, and legal counsel split between Cooley LLP and Latham & Watkins LLP. Overall, this filing materially advances the company's public market debut, enhancing liquidity and capital access for its life sciences operations.